ClinicalTrials.gov record
Active, not recruiting Phase 1 Interventional

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

ClinicalTrials.gov ID: NCT03740334

Public ClinicalTrials.gov record NCT03740334. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Trial of Ribociclib in Combination With Everolimus and Dexamethasone in Children and Young Adults With Relapsed Acute Lymphoblastic Leukemia

Study identification

NCT ID
NCT03740334
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Dana-Farber Cancer Institute
Other
Enrollment
45 participants

Conditions and interventions

Interventions

  • Dexamethasone Drug
  • Everolimus Drug
  • Ribociclib Drug

Drug

Eligibility (public fields only)

Age range
1 Year to 30 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 29, 2019
Primary completion
Mar 3, 2023
Completion
Sep 30, 2026
Last update posted
Nov 20, 2025

2019 – 2026

United States locations

U.S. sites
12
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Children's Hospital Colorado Aurora Colorado 80045
Nemours/Alfred I. duPont Hospital for Children Wilmington Delaware 19803
Children's Healthcare of Atlanta Atlanta Georgia 30322
Boston Children's Hospital Boston Massachusetts 02115
Dana Farber Cancer Institute Boston Massachusetts 02215
Dana-Farber Cancer Institute Boston Massachusetts 02215
Roswell Park Cancer Institute Buffalo New York 14263
Memorial Sloan Kettering Cancer Center New York New York 10174
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229
Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104
Texas Children's Hospital Houston Texas 77030
Children's Hospital of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03740334, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 20, 2025 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03740334 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →